Trial Profile
A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Penile cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ALPACA
- 01 Feb 2024 Planned End Date changed from 30 Jun 2023 to 31 Dec 2024.
- 01 Feb 2024 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 08 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2023.